Neovasc Inc. EV/FCF

EV/FCF of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/FCF of Neovasc Inc. is 0.38 (as of December 31, 2021)
  • EV/FCF for the quarter ending March 31, 2022 was 0.1 (a -73.32% decrease compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -139.22%
  • Annual EV/FCF for 2021 was 0.38 (a -160.57% decrease from previous year)
  • Annual EV/FCF for 2020 was -0.63 (a -65.83% decrease from previous year)
  • Annual EV/FCF for 2019 was -1.84 (a 193.87% increase from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of Neovasc Inc.

Most recent EV/FCFof NVCN including historical data for past 10 years.

Interactive Chart of EV/FCF of Neovasc Inc.

Neovasc Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.1
2021 0.38 -0.09 -0.26 0.24 0.38
2020 -0.63 -1.29 -1.12 -0.77 -0.63
2019 -1.84 -1.42 -1.38 -0.71 -1.84
2018 -0.63 -0.44 -0.42 -6.42 -0.63
2017 -0.37 2.77 2.52 3.21 -0.37
2016 3.47 -1.73 -1.92 -7.65 3.47
2015 -10.63 -13.33 -22.87 -39.04 -10.63
2014 -39.06 -43.01 -64.47 -51.62 -39.06
2013 -31.71 -23.51 -32.37 -38.94 -31.71
2012 -32.12 -15.35 0.0 0.0 -32.12
2011 0.0 0.0

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.